SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced the launch of a Cancer Analysis Service from the Illumina Genome Network (IGN) that leverages the high accuracy of Illumina technologies to provide cancer researchers with easily interpretable tumor/normal sequencing data to quickly move their research forward. IGN is designed to link researchers needing large-scale, whole human genome sequencing services with leading institutions that provide these services using industry-leading Illumina sequencing platforms powered by TruSeq® technology.
